Bulletin
Investor Alert

New York Markets Open in:

May 18, 2022, 3:57 p.m. EDT

Moderna to Present at the UBS 2022 Global Healthcare Conference

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)

or Cancel Already have a watchlist? Log In

May 18, 2022 (ACCESSWIRE via COMTEX) -- CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. /zigman2/quotes/205619834/composite MRNA +0.76% , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 [th] at 9:15 a.m. ET.

A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com . A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com .

Investors: .
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc

COMTEX_407413515/2457/2022-05-18T15:56:33

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 145.36
+1.09 +0.76%
Volume: 4.39M
June 27, 2022 4:00p
P/E Ratio
4.27
Dividend Yield
N/A
Market Cap
$57.38 billion
Rev. per Employee
$6.82M
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.